- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03256539
Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease
September 18, 2023 updated by: University of California, San Francisco
This study aimed to pilot test a non-pharmacological (behavioral) treatment program targeting improved cognition through improving 24-h sleep-wake cycle in people with mild cognitive impairment (MCI) or mild Alzheimer's disease.
A treatment program incorporating bright light therapy and a modified cognitive behavioral therapy for insomnia will be developed to address 24-hour patterns of sleep.
We will then pilot test its feasibility and explore its preliminary effects on improving sleep/napping and cognition in patients with MCI or mild Alzheimer's disease.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yue Leng, PhD
- Phone Number: 6565 4152214810
- Email: yue.leng@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94121
- Recruiting
- UCSF
-
Contact:
- Bernard Landavazo, MA
- Phone Number: 415-340-2708
- Email: bernard.landavazo@ucsf.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ≥65 years old
- Memory complaints verified by an informant
- Clinical diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's Disease
- General cognitive performance sufficiently persevered such that a diagnosis of Alzheimer's disease cannot be made by the site physician
- No evidence (CT or MRI scans within 12 months prior to screening) of infection, infarction, or other focal lesions and no clinical symptoms suggestive of intervening neurological disease
- Adequate visual and auditory acuity to allow neuropsychological testing
- Meets ICSD-2 criteria for insomnia or circadian rhythm disorders, or shows actigraphy evidence of sleep disturbances and excessive napping
Exclusion Criteria:
- Any major neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, multiple sclerosis, seizure disorder, Huntington's disease, brain tumor or history of significant head trauma
- Any comorbid psychiatric conditions or severe personality disorder within the past 2 years (by DSM-IV), such as major depression, bipolar disorder, schizophrenia and other psychotic features
- Any uncontrolled medical conditions or systemic illness that might lead to difficulty complying with the study protocol
- History of alcohol or substance abuse within the past 2 years
- Any inadequately treated primary or secondary sleep disorder (due to medical conditions) that might confound the association
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sleep Intervention
Sleep treatment program (to be developed) that incorporates modified cognitive behavioral therapy for insomnia (CBT-I) and bright light therapy (BLT)
|
Behavioral sleep intervention program
|
Placebo Comparator: Placebo intervention
Placebo (quasi-desensitization) intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration).
|
Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants enrolled to the study
Time Frame: Up to 24 weeks following study initiation
|
Up to 24 weeks following study initiation
|
Number of participants that complete the study
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep as assessed by actigraphy
Time Frame: Through study completion, an average of 1 year
|
Week-long measurement using wrist actigraphy
|
Through study completion, an average of 1 year
|
Cognitive function assessed by standard neurocognitive battery
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Yue Leng, PhD, University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 12, 2021
Primary Completion (Estimated)
January 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
August 8, 2017
First Submitted That Met QC Criteria
August 18, 2017
First Posted (Actual)
August 22, 2017
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 18, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1K99AG056598-01 (U.S. NIH Grant/Contract)
- R00AG056598 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
Stanford UniversityRecruitingMild Cognitive Impairment | Subjective Cognitive ImpairmentUnited States
-
Fondazione Don Carlo Gnocchi OnlusUniversity of Florence; Consorzio di Bioingeneria e Informatica Medica; Gutenberg...CompletedCognitive Dysfunction | Mild Cognitive Impairment | Vascular Cognitive ImpairmentItaly
-
University of California, Los AngelesCompletedMild Cognitive Impairment (MCI) | Age-associated Cognitive ImpairmentUnited States
-
Universidad de ZaragozaNot yet recruitingMild Cognitive Impairment | Randomized Controlled Trial | Subjective Cognitive Impairment
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Region SkaneLund University; Berry LabCompletedMemory Impairment | Cognitive Impairment, MildSweden
-
University of GeorgiaApplied Universal Dynamics, Corp.; Van Robotics, Inc.Active, not recruitingRobot-assisted Cognitive Training for Lonely Older Adults With Mild Cognitive Impairment (MCI) (MCI)Cognitive Change | Aging | Cognitive Impairment, MildUnited States
-
University Health Network, TorontoRecruiting
-
Wake Forest University Health SciencesActive, not recruiting
Clinical Trials on Sleep intervention
-
Stanford UniversityVA Palo Alto Health Care SystemCompletedDepression | Insomnia | Suicidal IdeationUnited States
-
University of California, Los AngelesVA Office of Research and DevelopmentRecruitingCardiovascular Diseases | Insomnia | Posttraumatic Stress Disorder | Metabolic DiseaseUnited States
-
University of ChicagoCompletedChronic Kidney DiseaseUnited States
-
National Taiwan University HospitalCompleted
-
University of British ColumbiaCanadian Cancer Society (CCS)Completed
-
Erasmus Medical CenterNational Institute for Public Health and the Environment (RIVM); Netherlands...RecruitingShift-Work Related Sleep DisturbanceNetherlands
-
US Department of Veterans AffairsCompletedInsomnia | Sleep DisordersUnited States
-
Wayne State UniversityCompletedStress, Emotional | Sleep DisturbanceUnited States
-
National Taiwan University HospitalRecruiting
-
Montana State UniversityNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting